---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001156"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T11:29:40.096701+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics to effect 1-for-100 reverse stock split to cure Nasdaq bid price deficiency

## Summary
- Reverse stock split at 1-for-100 ratio effective Jan 8, 2025; reduces outstanding shares from ~260M to ~2.6M.
- Company received Nasdaq delisting notice on Oct 24, 2024 after bid price ≤$0.10 for ten consecutive days.
- Company presented compliance plan to Nasdaq on Dec 17, 2024; believes reverse split will cure deficiency.
- No fractional shares issued; stockholders entitled to fractional shares will round up to whole share.

## SEC filing metadata
- accession: 0001213900-25-001156
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/0001213900-25-001156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/ea0226772-8k_cerotherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001156
- JSON: https://secwatch.observer/filing/0001213900-25-001156.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001156.txt

## Key facts
- Governance Changes
  CERO THERAPEUTICS HOLDINGS, INC.: Amended certificate of incorporation to effect a 1-for-100 reverse stock split (effective 2025-01-08).
  - Change: charter amendment
  - Effective: 2025-01-08
  source text: On January 6, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/0001213900-25-001156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.